Cargando…
Personalized immunosuppression in transplantation : role of biomarker monitoring and therapeutic drug monitoring /
Personalized Immunosuppression in Transplantation: Role of Biomarker Monitoring and Therapeutic Drug Monitoring provides coverage of the various approaches to monitoring immunosuppressants in transplant patients, including the most recently developed biomarker monitoring methods, pharmacogenomics ap...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam, Netherlands :
Elsevier,
[2016]
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Front Cover; Personalized Immunosuppression in Transplantation; Copyright Page; Contents; Preface; List of Contributors; 1 Overview of the pharmacology and toxicology of immunosuppressant agents that require therapeutic drug monitoring; 1.1 Introduction; 1.2 Calcineurin Inhibitors; 1.2.1 Cyclosporine A; 1.2.2 Tacrolimus; 1.3 Antimetabolite Drug; 1.4 Mammalian Target of Rapamycin Inhibitors; 1.4.1 Sirolimus (Rapamycin); 1.4.2 Everolimus (RAD001); 1.5 Conclusions; References; 2 Limitations of immunoassays used for therapeutic drug monitoring of immunosuppressants; 2.1 Introduction.
- 2.2 Methods for Therapeutic Drug Monitoring of Immunosuppressants2.3 Cyclosporine Monitoring: Trough or C2 Monitoring?; 2.4 Limitations of Immunoassays Used for Cyclosporine Monitoring; 2.5 Limitations of Immunoassays Used for Tacrolimus Monitoring; 2.6 Limitations of Immunoassays Used for Sirolimus Monitoring; 2.7 Limitations of Immunoassays Used for Everolimus Monitoring; 2.8 Limitations of Immunoassays Used for Mycophenolic Acid Monitoring; 2.9 Conclusions; References.
- 3 Application of liquid chromatography combined with mass spectrometry or tandem mass spectrometry for therapeutic drug mo ... 3.1 Introduction; 3.2 Evolution of Non-Immunoassay Methods for Immunosuppressants; 3.3 LC-MS/MS Methods for Analysis of Immunosuppressants; 3.3.1 Preanalytical Variable: Specimens; 3.3.2 Preanalytical Variable: Specimen Collection; 3.3.3 Preanalytical Variable: Drug-Drug Interactions; 3.3.4 Preanalytical Variable: Genetic Polymorphisms; 3.3.5 Preanalytical Variable: Clinical Status of the Patient; 3.3.6 Preanalytical Variable: Pregnancy.
- 3.3.7 Analytical Step: Specimen Preparation3.3.8 Analytical Step: Reagents; 3.3.9 Analytical Step: Solvents; 3.3.9.1 Proficiency testing; 3.4 Limitation of Mass Spectrometric Methods; 3.4.1 Ion Suppression/Enhancement; 3.4.1.1 Cross talk and in-source fragmentation; 3.4.1.2 Isobaric interferences; 3.5 Turnaround Time; 3.6 Conclusions; References; 4 Monitoring free mycophenolic acid concentration: Is there any clinical advantage?; 4.1 Introduction; 4.2 Monitoring Free Drug Concentration; 4.3 Monitoring Free (Unbound) Fraction of Cyclosporine.
- 4.4 Monitoring Free (Unbound) Fraction of Tacrolimus and Sirolimus4.5 Mycophenolic Acid: A Brief Introduction; 4.6 Rationale for Therapeutic Drug Monitoring of Mycophenolic Acid; 4.6.1 Serum Protein Binding of Mycophenolic Acid; 4.6.2 Conditions That Increase Free Mycophenolic Acid Level; 4.6.3 Clinical Utility of Monitoring Free Mycophenolic Acid; 4.6.4 Drug-Mycophenolic Acid Interaction; 4.6.5 Analytical Methods for Determination of Free Mycophenolic Acid; 4.7 Conclusion; References; 5 Pharmacogenomics aspect of immunosuppressant therapy; 5.1 Introduction; 5.2 Individual Genes.